{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:35:45Z","timestamp":1791329745801,"version":"4.3.1"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T00:00:00Z","timestamp":1482451200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Res"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/cr.2016.153","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T21:53:25Z","timestamp":1482616405000},"page":"59-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["Immunotherapy against cancer-related viruses"],"prefix":"10.1038","volume":"27","author":[{"given":"Haruko","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm K","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,23]]},"reference":[{"key":"BFcr2016153_CR1","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","volume":"118","author":"DM Parkin","year":"2006","unstructured":"Parkin DM . The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118:3030\u20133044.","journal-title":"Int J Cancer"},{"key":"BFcr2016153_CR2","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","volume":"4","author":"M Plummer","year":"2016","unstructured":"Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S . Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global health 2016; 4:e609\u2013e616.","journal-title":"The Lancet Global health"},{"key":"BFcr2016153_CR3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/14737140.2015.957189","volume":"15","author":"E Rettig","year":"2015","unstructured":"Rettig E, Kiess AP, Fakhry C . The role of sexual behavior in head and neck cancer: implications for prevention and therapy. Expert Rev Anticancer Ther 2015; 15:35\u201349.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFcr2016153_CR4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.chom.2014.02.011","volume":"15","author":"EA Mesri","year":"2014","unstructured":"Mesri EA, Feitelson MA, Munger K . Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 2014; 15:266\u2013282.","journal-title":"Cell Host Microbe"},{"key":"BFcr2016153_CR5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.4434","volume":"235","author":"M Ringelhan","year":"2015","unstructured":"Ringelhan M, O'Connor T, Protzer U, Heikenwalder M . The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol 2015; 235:355\u2013367.","journal-title":"J Pathol"},{"key":"BFcr2016153_CR6","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/onc.2010.594","volume":"30","author":"DR McGivern","year":"2011","unstructured":"McGivern DR, Lemon SM . Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011; 30:1969\u20131983.","journal-title":"Oncogene"},{"key":"BFcr2016153_CR7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.critrevonc.2008.07.021","volume":"70","author":"C de Martel","year":"2009","unstructured":"de Martel C, Franceschi S . Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol 2009; 70:183\u2013194.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFcr2016153_CR8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3109\/08820139.2015.1096680","volume":"44","author":"D Amsterdam","year":"2015","unstructured":"Amsterdam D . Immunotherapeutic approaches for the control and eradication of HIV. Immunol Invest 2015; 44:719\u2013730.","journal-title":"Immunol Invest"},{"key":"BFcr2016153_CR9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ni.3161","volume":"16","author":"SA Migueles","year":"2015","unstructured":"Migueles SA, Connors M . Success and failure of the cellular immune response against HIV-1. Nat Immunol 2015; 16:563\u2013570.","journal-title":"Nat Immunol"},{"key":"BFcr2016153_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.micro.112408.134019","volume":"64","author":"JT Schiller","year":"2010","unstructured":"Schiller JT, Lowy DR . Vaccines to prevent infections by oncoviruses. Annu Rev Microbiol 2010; 64:23\u201341.","journal-title":"Annu Rev Microbiol"},{"key":"BFcr2016153_CR11","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","volume":"21","author":"U Gerdemann","year":"2013","unstructured":"Gerdemann U, Katari UL, Papadopoulou A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 2013; 21:2113\u20132121.","journal-title":"Mol Ther"},{"key":"BFcr2016153_CR12","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123\u20131131.","journal-title":"Blood"},{"key":"BFcr2016153_CR13","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121:5113\u20135123.","journal-title":"Blood"},{"key":"BFcr2016153_CR14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/onc.2010.537","volume":"30","author":"M Matsuoka","year":"2011","unstructured":"Matsuoka M, Jeang KT . Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 2011; 30:1379\u20131389.","journal-title":"Oncogene"},{"key":"BFcr2016153_CR15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrc2888","volume":"10","author":"EA Mesri","year":"2010","unstructured":"Mesri EA, Cesarman E, Boshoff C . Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10:707\u2013719.","journal-title":"Nat Rev Cancer"},{"key":"BFcr2016153_CR16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.virol.2012.09.029","volume":"435","author":"ME Spurgeon","year":"2013","unstructured":"Spurgeon ME, Lambert PF . Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology 2013; 435:118\u2013130.","journal-title":"Virology"},{"key":"BFcr2016153_CR17","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11912-011-0197-5","volume":"13","author":"S Bhatia","year":"2011","unstructured":"Bhatia S, Afanasiev O, Nghiem P . Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep 2011; 13:488\u2013497.","journal-title":"Curr Oncol Rep"},{"key":"BFcr2016153_CR18","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/onc.2009.351","volume":"27","author":"D Martin","year":"2008","unstructured":"Martin D, Gutkind JS . Human tumor-associated viruses and new insights into the molecular mechanisms of cancer. Oncogene 2008; 27:S31\u2013S42.","journal-title":"Oncogene"},{"key":"BFcr2016153_CR19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nrc2961","volume":"10","author":"PS Moore","year":"2010","unstructured":"Moore PS, Chang Y . Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer 2010; 10:878\u2013889.","journal-title":"Nat Rev Cancer"},{"key":"BFcr2016153_CR20","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0959-8049(99)00291-9","volume":"35","author":"H zur Hausen","year":"1999","unstructured":"zur Hausen H . Viruses in human cancers. Eur J Cancer 1999; 35:1878\u20131885.","journal-title":"Eur J Cancer"},{"key":"BFcr2016153_CR21","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1128\/JVI.64.9.4084-4092.1990","volume":"64","author":"J Sample","year":"1990","unstructured":"Sample J, Young L, Martin B, Chatman T, Kieff E, Rickinson A . Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 1990; 64:4084\u20134092.","journal-title":"J Virol"},{"key":"BFcr2016153_CR22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.2008-0036","volume":"13","author":"A Carbone","year":"2008","unstructured":"Carbone A, Gloghini A, Dotti G . EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008; 13:577\u2013585.","journal-title":"Oncologist"},{"key":"BFcr2016153_CR23","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1158\/0008-5472.CAN-08-3301","volume":"68","author":"RT Javier","year":"2008","unstructured":"Javier RT, Butel JS . The history of tumor virology. Cancer Res 2008; 68:7693\u20137706.","journal-title":"Cancer Res"},{"key":"BFcr2016153_CR24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bbadis.2007.12.005","volume":"1782","author":"ME McLaughlin-Drubin","year":"2008","unstructured":"McLaughlin-Drubin ME, Munger K . Viruses associated with human cancer. Biochim Biophys Acta 2008; 1782:127\u2013150.","journal-title":"Biochim Biophys Acta"},{"key":"BFcr2016153_CR25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.1968.03140030037009","volume":"203","author":"JC Niederman","year":"1968","unstructured":"Niederman JC, McCollum RW, Henle G, Henle W . Infectious mononucleosis. Clinical manifestations in relation to EB virus antibodies. JAMA 1968; 203:205\u2013209.","journal-title":"JAMA"},{"key":"BFcr2016153_CR26","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2005-07-2702","volume":"107","author":"H Williams","year":"2006","unstructured":"Williams H, Crawford DH . Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006; 107:862\u2013869.","journal-title":"Blood"},{"key":"BFcr2016153_CR27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1128\/JVI.55.2.347-351.1985","volume":"55","author":"GR Nemerow","year":"1985","unstructured":"Nemerow GR, Wolfert R, McNaughton ME, Cooper NR . Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol 1985; 55:347\u2013351.","journal-title":"J Virol"},{"key":"BFcr2016153_CR28","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young LS, Rickinson AB . Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757\u2013768.","journal-title":"Nat Rev Cancer"},{"key":"BFcr2016153_CR29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm0602-594","volume":"8","author":"CM Borza","year":"2002","unstructured":"Borza CM, Hutt-Fletcher LM . Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nature medicine 2002; 8:594\u2013599.","journal-title":"Nature medicine"},{"key":"BFcr2016153_CR30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2008.01.006","volume":"29","author":"DA Thorley-Lawson","year":"2008","unstructured":"Thorley-Lawson DA, Duca KA, Shapiro M . Epstein-Barr virus: a paradigm for persistent infection \u2014 for real and in virtual reality. Trends Immunol 2008; 29:195\u2013201.","journal-title":"Trends Immunol"},{"key":"BFcr2016153_CR31","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","volume":"9","author":"CM Bollard","year":"2012","unstructured":"Bollard CM, Rooney CM, Heslop HE . T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol 2012; 9:510\u2013519.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFcr2016153_CR32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2217\/fon.09.53","volume":"5","author":"MA Morris","year":"2009","unstructured":"Morris MA, Dawson CW, Young LS . Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future oncology 2009; 5:811\u2013825.","journal-title":"Future oncology"},{"key":"BFcr2016153_CR33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","volume":"9","author":"RG Caldwell","year":"1998","unstructured":"Caldwell RG, Wilson JB, Anderson SJ, Longnecker R . Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998; 9:405\u2013411.","journal-title":"Immunity"},{"key":"BFcr2016153_CR34","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJM199509143331103","volume":"333","author":"R Pathmanathan","year":"1995","unstructured":"Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N . Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333:693\u2013698.","journal-title":"N Engl J Med"},{"key":"BFcr2016153_CR35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.4448","volume":"235","author":"SW Tsao","year":"2015","unstructured":"Tsao SW, Tsang CM, To KF, Lo KW . The role of Epstein-Barr virus in epithelial malignancies. J Pathol 2015; 235:323\u2013333.","journal-title":"J Pathol"},{"key":"BFcr2016153_CR36","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis 2007; 196:1749\u20131753.","journal-title":"J Infect Dis"},{"key":"BFcr2016153_CR37","doi-asserted-by":"crossref","first-page":"107fs107","DOI":"10.1126\/scitranslmed.3002878","volume":"3","author":"JI Cohen","year":"2011","unstructured":"Cohen JI, Fauci AS, Varmus H, Nabel GJ . Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 2011; 3:107fs107.","journal-title":"Sci Transl Med"},{"key":"BFcr2016153_CR38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","volume":"88","author":"L Rees","year":"2009","unstructured":"Rees L, Tizard EJ, Morgan AJ, et al. A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation 2009; 88:1025\u20131029.","journal-title":"Transplantation"},{"key":"BFcr2016153_CR39","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.01409-07","volume":"82","author":"SL Elliott","year":"2008","unstructured":"Elliott SL, Suhrbier A, Miles JJ, et al. Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 2008; 82:1448\u20131457.","journal-title":"J Virol"},{"key":"BFcr2016153_CR40","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1038\/cti.2014.27","volume":"4","author":"JI Cohen","year":"2015","unstructured":"Cohen JI . Epstein-barr virus vaccines. Clin Transl Immunology 2015; 4:e32.","journal-title":"Clin Transl Immunology"},{"key":"BFcr2016153_CR41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.coi.2010.12.014","volume":"23","author":"HM Long","year":"2011","unstructured":"Long HM, Taylor GS, Rickinson AB . Immune defence against EBV and EBV-associated disease. Curr Opin Immunol 2011; 23:258\u2013264.","journal-title":"Curr Opin Immunol"},{"key":"BFcr2016153_CR42","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor GS, Jia H, Harrington K, et al. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 2014; 20:5009\u20135022.","journal-title":"Clin Cancer Res"},{"key":"BFcr2016153_CR43","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","volume":"330","author":"EB Papadopoulos","year":"1994","unstructured":"Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185\u20131191.","journal-title":"N Engl J Med"},{"key":"BFcr2016153_CR44","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","volume":"115","author":"HE Heslop","year":"2010","unstructured":"Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925\u2013935.","journal-title":"Blood"},{"key":"BFcr2016153_CR45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","volume":"345","author":"CM Rooney","year":"1995","unstructured":"Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345:9\u201313.","journal-title":"Lancet"},{"key":"BFcr2016153_CR46","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119:2644\u20132656.","journal-title":"Blood"},{"key":"BFcr2016153_CR47","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","volume":"116","author":"JN Barker","year":"2010","unstructured":"Barker JN, Doubrovina E, Sauter C, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116:5045\u20135049.","journal-title":"Blood"},{"key":"BFcr2016153_CR48","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V95.3.807.003k24_807_814","volume":"95","author":"A Gustafsson","year":"2000","unstructured":"Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95:807\u2013814.","journal-title":"Blood"},{"key":"BFcr2016153_CR49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcmd.2007.06.020","volume":"40","author":"P Comoli","year":"2008","unstructured":"Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F . T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008; 40:68\u201370.","journal-title":"Blood Cells Mol Dis"},{"key":"BFcr2016153_CR50","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/blood.V99.7.2592","volume":"99","author":"P Comoli","year":"2002","unstructured":"Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002; 99:2592\u20132598.","journal-title":"Blood"},{"key":"BFcr2016153_CR51","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","volume":"108","author":"B Savoldo","year":"2006","unstructured":"Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108:2942\u20132949.","journal-title":"Blood"},{"key":"BFcr2016153_CR52","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.4049\/jimmunol.160.12.6204","volume":"160","author":"T Haque","year":"1998","unstructured":"Haque T, Amlot PL, Helling N, et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998; 160:6204\u20136209.","journal-title":"J Immunol"},{"key":"BFcr2016153_CR53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00262-009-0789-1","volume":"59","author":"M Uhlin","year":"2010","unstructured":"Uhlin M, Okas M, Gertow J, Uzunel M, Brismar TB, Mattsson J . A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 2010; 59:473\u2013477.","journal-title":"Cancer Immunol Immunother"},{"key":"BFcr2016153_CR54","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","volume":"115","author":"A Moosmann","year":"2010","unstructured":"Moosmann A, Bigalke I, Tischer J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010; 115:2960\u20132970.","journal-title":"Blood"},{"key":"BFcr2016153_CR55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/imr.12138","volume":"258","author":"AM Leen","year":"2014","unstructured":"Leen AM, Heslop HE, Brenner MK . Antiviral T-cell therapy. Immunol Rev 2014; 258:12\u201329.","journal-title":"Immunol Rev"},{"key":"BFcr2016153_CR56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.20040613","volume":"202","author":"M Cobbold","year":"2005","unstructured":"Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202:379\u2013386.","journal-title":"J Exp Med"},{"key":"BFcr2016153_CR57","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nm0602-631","volume":"8","author":"M Knabel","year":"2002","unstructured":"Knabel M, Franz TJ, Schiemann M, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 2002; 8:631\u2013637.","journal-title":"Nat Med"},{"key":"BFcr2016153_CR58","first-page":"427","volume":"391","author":"S Gottschalk","year":"2015","unstructured":"Gottschalk S, Rooney CM . Adoptive T-cell immunotherapy. Curr Top Microbiol Immunol 2015; 391:427\u2013454.","journal-title":"Curr Top Microbiol Immunol"},{"key":"BFcr2016153_CR59","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","volume":"6","author":"A Papadopoulou","year":"2014","unstructured":"Papadopoulou A, Gerdemann U, Katari UL, et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med 2014; 6:242ra83.","journal-title":"Sci Transl Med"},{"key":"BFcr2016153_CR60","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","volume":"360","author":"T Haque","year":"2002","unstructured":"Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360:436\u2013442.","journal-title":"Lancet"},{"key":"BFcr2016153_CR61","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1365-2141.2002.03683.x","volume":"118","author":"Q Sun","year":"2002","unstructured":"Sun Q, Burton R, Reddy V, Lucas KG . Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002; 118:799\u2013808.","journal-title":"Br J Haematol"},{"key":"BFcr2016153_CR62","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","volume":"91","author":"MA Roskrow","year":"1998","unstructured":"Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998; 91:2925\u20132934.","journal-title":"Blood"},{"key":"BFcr2016153_CR63","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1128\/JVI.75.18.8649-8659.2001","volume":"75","author":"A Leen","year":"2001","unstructured":"Leen A, Meij P, Redchenko I, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 2001; 75:8649\u20138659.","journal-title":"J Virol"},{"key":"BFcr2016153_CR64","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1073\/pnas.0813320106","volume":"106","author":"MH Fogg","year":"2009","unstructured":"Fogg MH, Wirth LJ, Posner M, Wang F . Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci USA 2009; 106:3318\u20133323.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcr2016153_CR65","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ijc.1396","volume":"93","author":"B Gahn","year":"2001","unstructured":"Gahn B, Siller-Lopez F, Pirooz AD, et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphoma. Int J Cancer 2001; 93:706\u2013713.","journal-title":"Int J Cancer"},{"key":"BFcr2016153_CR66","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2002-05-1514","volume":"101","author":"S Gottschalk","year":"2003","unstructured":"Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101:1905\u20131912.","journal-title":"Blood"},{"key":"BFcr2016153_CR67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CJI.0000000000000014","volume":"37","author":"MC Ngo","year":"2014","unstructured":"Ngo MC, Ando J, Leen AM, et al. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother 2014; 37:193\u2013203.","journal-title":"J Immunother"},{"key":"BFcr2016153_CR68","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/asheducation-2007.1.204","volume":"2007","author":"RF Ambinder","year":"2007","unstructured":"Ambinder RF . Epstein-barr virus and hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007; 2007:204\u2013209.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFcr2016153_CR69","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1056\/NEJM199904223401604","volume":"340","author":"A Brauninger","year":"1999","unstructured":"Brauninger A, Hansmann ML, Strickler JG, et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 1999; 340:1239\u20131247.","journal-title":"N Engl J Med"},{"key":"BFcr2016153_CR70","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ijc.2910460509","volume":"46","author":"TC Wu","year":"1990","unstructured":"Wu TC, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer 1990; 46:801\u2013804.","journal-title":"Int J Cancer"},{"key":"BFcr2016153_CR71","first-page":"1259","volume":"139","author":"LM Weiss","year":"1991","unstructured":"Weiss LM, Chen YY, Liu XF, Shibata D . Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. Am J Pathol 1991; 139:1259\u20131265.","journal-title":"Am J Pathol"},{"key":"BFcr2016153_CR72","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1182\/blood.V80.2.484.484","volume":"80","author":"H Herbst","year":"1992","unstructured":"Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood 1992; 80:484\u2013491.","journal-title":"Blood"},{"key":"BFcr2016153_CR73","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1182\/blood.V87.9.3828.bloodjournal8793828","volume":"87","author":"M Weinreb","year":"1996","unstructured":"Weinreb M, Day PJ, Niggli F, et al. The consistent association between Epstein-Barr virus and Hodgkin's disease in children in Kenya. Blood 1996; 87:3828\u20133836.","journal-title":"Blood"},{"key":"BFcr2016153_CR74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.2910550303","volume":"55","author":"XG Zhou","year":"1993","unstructured":"Zhou XG, Hamilton-Dutoit SJ, Yan QH, Pallesen G . The association between Epstein-Barr virus and Chinese Hodgkin's disease. Int J Cancer 1993; 55:359\u2013363.","journal-title":"Int J Cancer"},{"key":"BFcr2016153_CR75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-004-0939-7","volume":"84","author":"AM Muller","year":"2005","unstructured":"Muller AM, Ihorst G, Mertelsmann R, Engelhardt M . Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84:1\u201312.","journal-title":"Ann Hematol"},{"key":"BFcr2016153_CR76","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1158\/1078-0432.CCR-0670-3","volume":"10","author":"MP Thompson","year":"2004","unstructured":"Thompson MP, Kurzrock R . Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10:803\u2013821.","journal-title":"Clin Cancer Res"},{"key":"BFcr2016153_CR77","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/asheducation-2005.1.260","volume":"2005","author":"HE Heslop","year":"2005","unstructured":"Heslop HE . Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2005; 2005:260\u2013266.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFcr2016153_CR78","doi-asserted-by":"crossref","first-page":"12168","DOI":"10.1038\/srep12168","volume":"5","author":"TX Lu","year":"2015","unstructured":"Lu TX, Liang JH, Miao Y, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep 2015; 5:12168.","journal-title":"Sci Rep"},{"key":"BFcr2016153_CR79","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.1999.17.3.825","volume":"17","author":"KS Baker","year":"1999","unstructured":"Baker KS, Gordon BG, Gross TG, et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999; 17:825\u2013831.","journal-title":"J Clin Oncol"},{"key":"BFcr2016153_CR80","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood.V90.8.2921","volume":"90","author":"R Ladenstein","year":"1997","unstructured":"Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T . High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt's lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood 1997; 90:2921\u20132930.","journal-title":"Blood"},{"key":"BFcr2016153_CR81","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.beha.2008.06.002","volume":"21","author":"CM Bollard","year":"2008","unstructured":"Bollard CM, Cooper LJ, Heslop HE . Immunotherapy targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol 2008; 21:405\u2013420.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFcr2016153_CR82","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014; 32:798\u2013808.","journal-title":"J Clin Oncol"},{"key":"BFcr2016153_CR83","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/mt.2015.91","volume":"23","author":"SG Cho","year":"2015","unstructured":"Cho SG, Kim N, Sohn HJ, et al. Long-term outcome of extranodal NK\/T cell lymphoma patients treated with postremission therapy using EBV LMP1 and LMP2a-specific CTLs. Mol Ther 2015; 23:1401\u20131409.","journal-title":"Mol Ther"},{"key":"BFcr2016153_CR84","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1535-6108(04)00119-9","volume":"5","author":"KW Lo","year":"2004","unstructured":"Lo KW, To KF, Huang DP . Focus on nasopharyngeal carcinoma. Cancer Cell 2004; 5:423\u2013428.","journal-title":"Cancer Cell"},{"key":"BFcr2016153_CR85","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/CJI.0b013e3181f3cbf4","volume":"33","author":"CU Louis","year":"2010","unstructured":"Louis CU, Straathof K, Bollard CM, et al. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 2010; 33:983\u2013990.","journal-title":"J Immunother"},{"key":"BFcr2016153_CR86","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1182\/blood-2004-07-2975","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005; 105:1898\u20131904.","journal-title":"Blood"},{"key":"BFcr2016153_CR87","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","volume":"23","author":"P Comoli","year":"2005","unstructured":"Comoli P, Pedrazzoli P, Maccario R, et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23:8942\u20138949.","journal-title":"J Clin Oncol"},{"key":"BFcr2016153_CR88","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1093\/annonc\/mdr134","volume":"23","author":"S Secondino","year":"2012","unstructured":"Secondino S, Zecca M, Licitra L, et al. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Ann Oncol 2012; 23:435\u2013441.","journal-title":"Ann Oncol"},{"key":"BFcr2016153_CR89","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","volume":"22","author":"WK Chia","year":"2014","unstructured":"Chia WK, Teo M, Wang WW, et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma. Mol Ther 2014; 22:132\u2013139.","journal-title":"Mol Ther"},{"key":"BFcr2016153_CR90","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1098\/rstb.2000.0783","volume":"356","author":"DH Crawford","year":"2001","unstructured":"Crawford DH . Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001; 356:461\u2013473.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"BFcr2016153_CR91","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.3390\/v4123420","volume":"4","author":"H Iizasa","year":"2012","unstructured":"Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H . Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses 2012; 4:3420\u20133439.","journal-title":"Viruses"},{"key":"BFcr2016153_CR92","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/jcp.2003.014068","volume":"57","author":"A Zur Hausen","year":"2004","unstructured":"Zur Hausen A, van Rees BP, van Beek J, et al. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol 2004; 57:487\u2013491.","journal-title":"J Clin Pathol"},{"key":"BFcr2016153_CR93","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.20040121","volume":"199","author":"SP Lee","year":"2004","unstructured":"Lee SP, Brooks JM, Al-Jarrah H, et al. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med 2004; 199:1409\u20131420.","journal-title":"J Exp Med"},{"key":"BFcr2016153_CR94","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.20031219","volume":"199","author":"KS Voo","year":"2004","unstructured":"Voo KS, Fu T, Wang HY, et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 2004; 199:459\u2013470.","journal-title":"J Exp Med"},{"key":"BFcr2016153_CR95","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20040730","volume":"199","author":"C Munz","year":"2004","unstructured":"Munz C . Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J Exp Med 2004; 199:1301\u20131304.","journal-title":"J Exp Med"},{"key":"BFcr2016153_CR96","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1084\/jem.191.10.1649","volume":"191","author":"C Munz","year":"2000","unstructured":"Munz C, Bickham KL, Subklewe M, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000; 191:1649\u20131660.","journal-title":"J Exp Med"},{"key":"BFcr2016153_CR97","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.4049\/jimmunol.169.3.1593","volume":"169","author":"C Paludan","year":"2002","unstructured":"Paludan C, Bickham K, Nikiforow S, et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002; 169:1593\u20131603.","journal-title":"J Immunol"},{"key":"BFcr2016153_CR98","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1128\/JVI.75.8.3740-3752.2001","volume":"75","author":"S Nikiforow","year":"2001","unstructured":"Nikiforow S, Bottomly K, Miller G . CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 2001; 75:3740\u20133752.","journal-title":"J Virol"},{"key":"BFcr2016153_CR99","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood-2014-01-553362","volume":"124","author":"I Ricciardelli","year":"2014","unstructured":"Ricciardelli I, Blundell MP, Brewin J, Thrasher A, Pule M, Amrolia PJ . Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 2014; 124:2514\u20132522.","journal-title":"Blood"},{"key":"BFcr2016153_CR100","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1182\/blood-2009-07-230482","volume":"114","author":"B De Angelis","year":"2009","unstructured":"De Angelis B, Dotti G, Quintarelli C, et al. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009; 114:4784\u20134791.","journal-title":"Blood"},{"key":"BFcr2016153_CR101","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/mt.2011.179","volume":"19","author":"LE Huye","year":"2011","unstructured":"Huye LE, Nakazawa Y, Patel MP, et al. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Mol Ther 2011; 19:2239\u20132248.","journal-title":"Mol Ther"},{"key":"BFcr2016153_CR102","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1099\/0022-1317-79-7-1631","volume":"79","author":"I Johannessen","year":"1998","unstructured":"Johannessen I, Haque T, N'Jie-Jobe J, Crawford DH . Non-correlation of in vivo and in vitro parameters of Epstein-Barr virus persistence suggests heterogeneity of B cell infection. J Gen Virol 1998; 79:1631\u20131636.","journal-title":"J Gen Virol"},{"key":"BFcr2016153_CR103","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/mt.2009.34","volume":"17","author":"JF Vera","year":"2009","unstructured":"Vera JF, Hoyos V, Savoldo B, et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009; 17:880\u2013888.","journal-title":"Mol Ther"},{"key":"BFcr2016153_CR104","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119:4133\u20134141.","journal-title":"Blood"},{"key":"BFcr2016153_CR105","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","volume":"99","author":"CM Bollard","year":"2002","unstructured":"Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002; 99:3179\u20133187.","journal-title":"Blood"},{"key":"BFcr2016153_CR106","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mt.2014.47","volume":"22","author":"AM Leen","year":"2014","unstructured":"Leen AM, Sukumaran S, Watanabe N, et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther 2014; 22:1211\u20131220.","journal-title":"Mol Ther"},{"key":"BFcr2016153_CR107","doi-asserted-by":"crossref","first-page":"11451","DOI":"10.1128\/JVI.78.21.11451-11460.2004","volume":"78","author":"K Munger","year":"2004","unstructured":"Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78:11451\u201311460.","journal-title":"J Virol"},{"key":"BFcr2016153_CR108","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","volume":"384","author":"H zur Hausen","year":"2009","unstructured":"zur Hausen H . Papillomaviruses in the causation of human cancers \u2014 a brief historical account. Virology 2009; 384:260\u2013265.","journal-title":"Virology"},{"key":"BFcr2016153_CR109","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1038\/sj.onc.1202953","volume":"18","author":"M Thomas","year":"1999","unstructured":"Thomas M, Pim D, Banks L . The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999; 18:7690\u20137700.","journal-title":"Oncogene"},{"key":"BFcr2016153_CR110","doi-asserted-by":"crossref","first-page":"e1000397","DOI":"10.1371\/journal.ppat.1000397","volume":"5","author":"M Kadaja","year":"2009","unstructured":"Kadaja M, Isok-Paas H, Laos T, Ustav E, Ustav M . Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog 2009; 5:e1000397.","journal-title":"PLoS Pathog"},{"key":"BFcr2016153_CR111","first-page":"3780","volume":"48","author":"M von Knebel Doeberitz","year":"1988","unstructured":"von Knebel Doeberitz M, Oltersdorf T, Schwarz E, Gissmann L . Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988; 48:3780\u20133786.","journal-title":"Cancer Res"},{"key":"BFcr2016153_CR112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fonc.2016.00019","volume":"6","author":"AL Beavis","year":"2016","unstructured":"Beavis AL, Levinson KL . Preventing cervical cancer in the United States: barriers and resolutions for HPV vaccination. Front Oncol 2016; 6:19.","journal-title":"Front Oncol"},{"key":"BFcr2016153_CR113","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711\u2013723.","journal-title":"N Engl J Med"},{"key":"BFcr2016153_CR114","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/14740338.2015.1013532","volume":"14","author":"M Stillo","year":"2015","unstructured":"Stillo M, Carrillo Santisteve P, Lopalco PL . Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf 2015; 14:697\u2013712.","journal-title":"Expert Opin Drug Saf"},{"key":"BFcr2016153_CR115","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/jcm4040614","volume":"4","author":"N Kash","year":"2015","unstructured":"Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK . Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus. J Clin Med 2015; 4:614\u2013633.","journal-title":"J Clin Med"},{"key":"BFcr2016153_CR116","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1038\/ncomms6317","volume":"5","author":"TJ Kim","year":"2014","unstructured":"Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun 2014; 5:5317.","journal-title":"Nat Commun"},{"key":"BFcr2016153_CR117","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","volume":"33","author":"S Stevanovic","year":"2015","unstructured":"Stevanovic S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015; 33:1543\u20131550.","journal-title":"J Clin Oncol"},{"key":"BFcr2016153_CR118","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","volume":"21","author":"LM Draper","year":"2015","unstructured":"Draper LM, Kwong ML, Gros A, et al. Targeting of HPV-16+ epithelial cancer cells by tcr gene engineered t cells directed against E6. Clin Cancer Res 2015; 21:4431\u20134439.","journal-title":"Clin Cancer Res"},{"key":"BFcr2016153_CR119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/CJI.0b013e318279652e","volume":"36","author":"CA Ramos","year":"2013","unstructured":"Ramos CA, Narala N, Vyas GM, et al. Human papillomavirus type 16 E6\/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother 2013; 36:66\u201376.","journal-title":"J Immunother"},{"key":"BFcr2016153_CR120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244:359\u2013362.","journal-title":"Science"},{"key":"BFcr2016153_CR121","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1001\/jama.284.4.450","volume":"284","author":"DL Thomas","year":"2000","unstructured":"Thomas DL, Strathdee SA, Vlahov D . Long-term prognosis of Hepatitis C virus infection. JAMA 2000; 284:2592.","journal-title":"JAMA"},{"key":"BFcr2016153_CR122","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrc1934","volume":"6","author":"PA Farazi","year":"2006","unstructured":"Farazi PA, DePinho RA . Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6:674\u2013687.","journal-title":"Nat Rev Cancer"},{"key":"BFcr2016153_CR123","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1386-6532(05)00384-7","volume":"34","author":"D Lavanchy","year":"2005","unstructured":"Lavanchy D . Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34:S1\u2013S3.","journal-title":"J Clin Virol"},{"key":"BFcr2016153_CR124","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/apt.13300","volume":"42","author":"LI Backus","year":"2015","unstructured":"Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA . Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015; 42:559\u2013573.","journal-title":"Aliment Pharmacol Ther"},{"key":"BFcr2016153_CR125","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/cncr.28730","volume":"120","author":"ZV Fong","year":"2014","unstructured":"Fong ZV, Tanabe KK . The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 2014; 120:2824\u20132838.","journal-title":"Cancer"},{"key":"BFcr2016153_CR126","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.critrevonc.2015.10.017","volume":"98","author":"C Bozza","year":"2016","unstructured":"Bozza C, Cinausero M, Iacono D, Puglisi F . Hepatitis B and cancer: A practical guide for the oncologist. Crit Rev Oncol Hematol 2016; 98:137\u2013146.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFcr2016153_CR127","first-page":"115","volume":"79","author":"JB Liao","year":"2006","unstructured":"Liao JB . Viruses and human cancer. Yale J Biol Med 2006; 79:115\u2013122.","journal-title":"Yale J Biol Med"},{"key":"BFcr2016153_CR128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2016.01.005","volume":"39","author":"M Tagliamonte","year":"2016","unstructured":"Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, Buonaguro L . Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol 2016; 39:103\u2013113.","journal-title":"Curr Opin Immunol"},{"key":"BFcr2016153_CR129","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2013.05.031","volume":"59","author":"L Buonaguro","year":"2013","unstructured":"Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM . Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol 2013; 59:897\u2013903.","journal-title":"J Hepatol"},{"key":"BFcr2016153_CR130","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","volume":"356","author":"T Takayama","year":"2000","unstructured":"Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356:802\u2013807.","journal-title":"Lancet"},{"key":"BFcr2016153_CR131","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/14653249.2011.649185","volume":"14","author":"Y Ma","year":"2012","unstructured":"Ma Y, Zhang Z, Tang L, et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012; 14:483\u2013493.","journal-title":"Cytotherapy"},{"key":"BFcr2016153_CR132","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.clinre.2014.04.010","volume":"38","author":"X Li","year":"2014","unstructured":"Li X, Dai D, Song X, Liu J, Zhu L, Xu W . A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2014; 38:583\u2013591.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"BFcr2016153_CR133","doi-asserted-by":"crossref","first-page":"41339","DOI":"10.18632\/oncotarget.5463","volume":"6","author":"SS Jiang","year":"2015","unstructured":"Jiang SS, Tang Y, Zhang YJ, et al. A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Oncotarget 2015; 6:41339\u201341349.","journal-title":"Oncotarget"},{"key":"BFcr2016153_CR134","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/01.cji.0000171291.72039.e2","volume":"28","author":"WC Lee","year":"2005","unstructured":"Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF . Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28:496\u2013504.","journal-title":"J Immunother"},{"key":"BFcr2016153_CR135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2407-10-209","volume":"10","author":"TF Greten","year":"2010","unstructured":"Greten TF, Forner A, Korangy F, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010; 10:209.","journal-title":"BMC Cancer"},{"key":"BFcr2016153_CR136","first-page":"5902","volume":"9","author":"LH Butterfield","year":"2003","unstructured":"Butterfield LH, Ribas A, Meng WS, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003; 9:5902\u20135908.","journal-title":"Clin Cancer Res"},{"key":"BFcr2016153_CR137","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4161\/onci.1.1.18344","volume":"1","author":"AD Pardee","year":"2012","unstructured":"Pardee AD, Butterfield LH . Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012; 1:48\u201355.","journal-title":"Oncoimmunology"},{"key":"BFcr2016153_CR138","doi-asserted-by":"crossref","first-page":"83","DOI":"10.57187\/smw.2007.11077","volume":"137","author":"LH Butterfield","year":"2007","unstructured":"Butterfield LH . Recent advances in immunotherapy for hepatocellular cancer. Swiss Med Wkly 2007; 137:83\u201390.","journal-title":"Swiss Med Wkly"},{"key":"BFcr2016153_CR139","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm.4015","volume":"22","author":"CA Klebanoff","year":"2016","unstructured":"Klebanoff CA, Rosenberg SA, Restifo NP . Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 2016; 22:26\u201336.","journal-title":"Nat Med"},{"key":"BFcr2016153_CR140","doi-asserted-by":"crossref","first-page":"11398","DOI":"10.1128\/JVI.01177-06","volume":"80","author":"S Urbani","year":"2006","unstructured":"Urbani S, Amadei B, Tola D, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80:11398\u201311403.","journal-title":"J Virol"},{"key":"BFcr2016153_CR141","doi-asserted-by":"crossref","first-page":"451694","DOI":"10.1155\/2011\/451694","volume":"2011","author":"KA Hofmeyer","year":"2011","unstructured":"Hofmeyer KA, Jeon H, Zang X . The PD-1\/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol 2011; 2011:451694.","journal-title":"J Biomed Biotechnol"},{"key":"BFcr2016153_CR142","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M . Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15:486\u2013499.","journal-title":"Nat Rev Immunol"},{"key":"BFcr2016153_CR143","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711\u2013723.","journal-title":"N Engl J Med"},{"key":"BFcr2016153_CR144","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443\u20132454.","journal-title":"N Engl J Med"},{"key":"BFcr2016153_CR145","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455\u20132465.","journal-title":"N Engl J Med"},{"key":"BFcr2016153_CR146","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311\u2013319.","journal-title":"N Engl J Med"},{"key":"BFcr2016153_CR147","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/mt.2014.91","volume":"22","author":"F Zhang","year":"2014","unstructured":"Zhang F, Zhou X, DiSpirito JR, Wang C, Wang Y, Shen H . Epigenetic manipulation restores functions of defective CD8(+) T cells from chronic viral infection. Mol Ther 2014; 22:1698\u20131706.","journal-title":"Mol Ther"},{"key":"BFcr2016153_CR148","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.coviro.2013.04.005","volume":"3","author":"DA Thorley-Lawson","year":"2013","unstructured":"Thorley-Lawson DA, Hawkins JB, Tracy SI, Shapiro M . The pathogenesis of Epstein-Barr virus persistent infection. Curr Opin Virol 2013; 3:227\u2013232.","journal-title":"Curr Opin Virol"},{"key":"BFcr2016153_CR149","doi-asserted-by":"crossref","first-page":"e1000496","DOI":"10.1371\/journal.ppat.1000496","volume":"5","author":"V Hadinoto","year":"2009","unstructured":"Hadinoto V, Shapiro M, Sun CC, Thorley-Lawson DA . The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog 2009; 5:e1000496.","journal-title":"PLoS Pathog"}],"container-title":["Cell Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cr2016153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cr2016153","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cr2016153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T12:34:43Z","timestamp":1692621283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cr2016153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,23]]},"references-count":149,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFcr2016153"],"URL":"https:\/\/doi.org\/10.1038\/cr.2016.153","relation":{},"ISSN":["1001-0602","1748-7838"],"issn-type":[{"value":"1001-0602","type":"print"},{"value":"1748-7838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,23]]},"assertion":[{"value":"23 December 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}